ABL1 (M351T)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.M351T
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 99.6% | 0.4% | 78.23 |
| 2 | Nintedanib | 99.3% | 0.7% | 90.23 |
| 3 | Bosutinib | 99.3% | 0.7% | 87.22 |
| 4 | Axitinib | 98.9% | 1.1% | 93.23 |
| 5 | Vandetanib | 97.6% | 2.4% | 95.74 |
| 6 | Dasatinib | 97.5% | 2.5% | 87.97 |
| 7 | Repotrectinib | 97.3% | 2.7% | 84.21 |
| 8 | Nilotinib | 96.5% | 3.5% | 96.49 |
| 9 | Crizotinib | 95.1% | 4.9% | 91.39 |
| 10 | Pacritinib | 94.1% | 5.9% | 88.64 |
| 11 | Canertinib | 93.5% | 6.5% | 96.49 |
| 12 | Tivozanib | 90.1% | 9.9% | 92.42 |
| 13 | Erdafitinib | 86.0% | 14.0% | 95.71 |
| 14 | Dacomitinib | 81.5% | 18.5% | 97.99 |
| 15 | Brigatinib | 79.6% | 20.4% | 82.96 |
| 16 | Erlotinib | 79.3% | 20.7% | 99.75 |
| 17 | Sunitinib | 75.2% | 24.8% | 91.73 |
| 18 | Fedratinib | 72.0% | 28.0% | 96.21 |
| 19 | Ripretinib | 68.3% | 31.7% | 92.95 |
| 20 | Afatinib | 64.5% | 35.5% | 98.50 |
| 21 | Entrectinib | 63.6% | 36.4% | 93.69 |
| 22 | Alectinib | 63.3% | 36.7% | 95.49 |
| 23 | Avapritinib | 55.5% | 44.5% | 97.73 |
| 24 | Gilteritinib | 52.5% | 47.5% | 88.97 |
| 25 | Imatinib | 51.7% | 48.3% | 99.00 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 99.6% | 100.0% | -0.4% |
| Nintedanib | 99.3% | 99.9% | -0.6% |
| Bosutinib | 99.3% | 99.7% | -0.5% |
| Axitinib | 98.9% | 99.4% | -0.5% |
| Vandetanib | 97.6% | 95.7% | +1.9% |
| Dasatinib | 97.5% | 98.6% | -1.1% |
| Repotrectinib | 97.3% | 93.6% | +3.7% |
| Nilotinib | 96.5% | 98.0% | -1.5% |
| Crizotinib | 95.1% | 97.0% | -1.9% |
| Pacritinib | 94.1% | 92.0% | +2.1% |
| Canertinib | 93.5% | 91.6% | +1.9% |
| Tivozanib | 90.1% | 95.8% | -5.7% |
| Erdafitinib | 86.0% | 90.9% | -4.9% |
| Dacomitinib | 81.5% | 80.8% | +0.7% |
| Brigatinib | 79.6% | 82.8% | -3.2% |
| Erlotinib | 79.3% | — | — |
| Sunitinib | 75.2% | — | — |
| Fedratinib | 72.0% | 82.7% | -10.7% |
| Ripretinib | 68.3% | 82.9% | -14.6% |
| Afatinib | 64.5% | — | — |
| Entrectinib | 63.6% | — | — |
| Alectinib | 63.3% | — | — |
| Avapritinib | 55.5% | — | — |
| Gilteritinib | 52.5% | — | — |
| Imatinib | 51.7% | 86.2% | -34.4% |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.2ms